Loading…
DWTX
Dogwood Therapeutics, Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 92829J203
$2.65+14.22%Price as of Aug 29, 18:45 UTC · updated once a day, after the close
Key metrics
- Market cap
- $90.08M
- P/E
- 1.2x
- Forward P/E
- —
- P/B
- 1.3x
- Dividend yield
- —
- Payout
- —
- EPS
- $2.13
- ROE
- -47.77%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.76
- 52-week high
- $9.50
- 52-week low
- $1.28
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -98.8% over 5Y.
today you would have $10.28▼ -99.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 6 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $4.16 | $2.49 | $14.38 | $5.90 | $127.88 | $187.75 | |
| P/B | 2.1x | 1.9x | — | 2.9x | 0.6x | 2.9x | 2.1x |
| EPS | -$7.13 | -$12.52 | -$7.05 | -$27.75 | -$48.00 | -$52.50 | |
| ROE | -110.06% | -45.74% |
Fair price, seven ways
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
Earnings
$9.87
Square root of 22.5 × earnings × book value — the two ceilings Graham proposed. Blind to intangibles, so it undervalues software and brands.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Operating
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ICCCImmucell Corp | $9.94 | 142.0x | 2.9x | — | 2.57% | $90.28M |
| RLYBRallybio Corp | $16.86 | 2.1x | 0.9x | — | 64.86% | $89.57M |
| ATRAAtara Biotherapeutics, Inc. | $8.81 | — | — | — | — | $88.43M |
| HYPRHyperfine, Inc. | $0.83 |
About the company
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is based in Alpharetta, Georgia.
- 8
- Alpharetta, United States
Company description provided by Yahoo Finance.